SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: icanpickem who started this subject4/29/2003 12:47:28 PM
From: bob zagorin  Read Replies (1) of 3044
 
fwiw
Nadine Wong Highlights the Following Stock: Millennium Pharmaceuticals

CHICAGO, Apr 29, 2003 (BUSINESS WIRE) -- Nadine Wong says the biotech industry
is emerging from a cyclical trough, so investors looking to strike while the
drugs are hot should consider one of her recommendations that could be a major
presence for a very long time. Get her take on Millennium (NASDAQ: MLNM). Click
here for the full story exclusively on Zacks.com:
featuredexpert2bw.zacks.com

Here are the highlights from the Featured Expert column:

Now that the uncertainties about the war in Iraq are largely determined, Wall
Street is again focusing on fundamentals - earnings and the U.S. economy. While
concern over quarterly earnings has weighed down many companies, the
biotechnology industry is looking better.

For Millennium (NASDAQ: MLNM), the story is Velcade, a promising developmental
compound currently in Phase III clinical trials for the treatment of multiple
myeloma. Velcade's developmental path will determine Millennium's success.
Management remains confident that it will find a partner for Velcade in the
second quarter to market the compound. Millennium anticipates Velcade will
receive FDA approval by mid-2003, and is hoping Velcade can be launched later
this year.

Millennium is a momentum stock, fueled by anticipation. Nadine Wong thinks the
Velcade story is a good one, and thinks the odds are in favor for FDA approval
this year.

Keep tabs on the progress of Millennium and the entire biotechnology space by
using Nadine Wong's detailed analysis by clicking:
featuredexpert3bw.zacks.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News